Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

Toshihiko Ishii, Asher Alban Chanan-Khan, MD, Jazur Jafferjee, MD, Noreen Ersing, Takeshi Takahashi, PhD, Masato Mizutani, PhD, Yukimasa Shiotsu, PhD, Nobuo Hanai, PhD

Blood (2008) 112 (11): 1718.

https://doi.org/10.1182/blood.V112.11.1718.1718

Published: 2008

Journal Articles

Survival Signals, Growth Cytokines, Immunosuppressive Factors and Their Cellular Perpetrators in the Myeloma Tumor Microenvironment.

Jayakumar R Nair, PhD, Louise M Carlson, PhD, Noreen Ersing, MS, Asher Alban Chanan-Khan, MD, Kelvin P. Lee, MD

Blood (2008) 112 (11): 1664.

https://doi.org/10.1182/blood.V112.11.1664.1664

Published: 2008

Journal Articles

Antiproliferative and Proapoptotic Effect of Vitamin D in Bortezomib (B) Resistant Human Myeloma Cell Line (HMCL).

Asher Alban Chanan-Khan, MD, Michelle Romano, Paula Pera, Noreen Ersing, Josephia Muindi, MD, Donald L. Trump, MD, Candace Johnson, MD

Blood (2006) 108 (11): 5074.

https://doi.org/10.1182/blood.V108.11.5074.5074

Published: 2006

Journal Articles

Characterization of Bortezomib Resistant Human Multiple Myeloma Cell Line (HMCL): A Clinically Relevant Model for Novel Drug Development in Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, Noreen Ersing, Paula Pera, Ralph Bernaki, Ph.D., Lionel Coignet, Ph.D., David W. Goodrich, Ph.D., Raya Haung, Ph.D., Carl W. Porter, Ph.D.

Blood (2006) 108 (11): 5050.

https://doi.org/10.1182/blood.V108.11.5050.5050

Published: 2006

Journal Articles

Pro-Apoptotic Effect of Lenalidomide (L) in Patients with Chronic Lymphocytic Leukemia (CLL) Is Possibly Mediated through Interruption of the Phosphatidylinositol Pathway.

Asher Alban Chanan-Khan, MD, Noreen Ersing, Deborah Krammer, Ralph Bernacki, Lionel Coignet, David Goodrich, Naveen Bangia, Swami Padmanabhan, Carl W. Porter

Blood (2006) 108 (11): 2102.

https://doi.org/10.1182/blood.V108.11.2102.2102

Published: 2006

Journal Articles

First Clinical Evidence of In Vivo Natural Killer (NK) Cell Modulation in Chronic Lymphocytic Leukemia (CLL) Patients (pts) Treated with Lenalidomide (L).

Swaminathan Padmanabhan, MD, Noreen Ersing, Ph.D, Paul K. Wallace, Ph.D, Kena C. Miller, RNP, Laurie Musiel, RNP, Micheal Rickert, Asher Alban Chanan-Khan, MD

Blood (2006) 108 (11): 2109.

https://doi.org/10.1182/blood.V108.11.2109.2109

Published: 2006

Journal Articles

In Vivo Evaluation of Immunomodulating Effects of Lenalidomide (L) on Tumor Cell Microenvironment as a Possible Underlying Mechanism of the Antitumor Effects Observed in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Asher Alban Chanan-Khan, MD, Swaminathan Padmanabhan, MD, Kena C. Miller, NP, Paula Pera, Laurie DiMiceli, Noreen Ersing, Paul Wallace, MD, Michael Rickert, Carl Porter, MD

Blood (2005) 106 (11): 2975.

https://doi.org/10.1182/blood.V106.11.2975.2975

Published: 2005

NARROW

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

Survival Signals, Growth Cytokines, Immunosuppressive Factors and Their Cellular Perpetrators in the Myeloma Tumor Microenvironment.

Antiproliferative and Proapoptotic Effect of Vitamin D in Bortezomib (B) Resistant Human Myeloma Cell Line (HMCL).

Characterization of Bortezomib Resistant Human Multiple Myeloma Cell Line (HMCL): A Clinically Relevant Model for Novel Drug Development in Multiple Myeloma (MM).

Pro-Apoptotic Effect of Lenalidomide (L) in Patients with Chronic Lymphocytic Leukemia (CLL) Is Possibly Mediated through Interruption of the Phosphatidylinositol Pathway.

First Clinical Evidence of In Vivo Natural Killer (NK) Cell Modulation in Chronic Lymphocytic Leukemia (CLL) Patients (pts) Treated with Lenalidomide (L).

In Vivo Evaluation of Immunomodulating Effects of Lenalidomide (L) on Tumor Cell Microenvironment as a Possible Underlying Mechanism of the Antitumor Effects Observed in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

Survival Signals, Growth Cytokines, Immunosuppressive Factors and Their Cellular Perpetrators in the Myeloma Tumor Microenvironment.

Antiproliferative and Proapoptotic Effect of Vitamin D in Bortezomib (B) Resistant Human Myeloma Cell Line (HMCL).

Characterization of Bortezomib Resistant Human Multiple Myeloma Cell Line (HMCL): A Clinically Relevant Model for Novel Drug Development in Multiple Myeloma (MM).

Pro-Apoptotic Effect of Lenalidomide (L) in Patients with Chronic Lymphocytic Leukemia (CLL) Is Possibly Mediated through Interruption of the Phosphatidylinositol Pathway.

First Clinical Evidence of In Vivo Natural Killer (NK) Cell Modulation in Chronic Lymphocytic Leukemia (CLL) Patients (pts) Treated with Lenalidomide (L).

In Vivo Evaluation of Immunomodulating Effects of Lenalidomide (L) on Tumor Cell Microenvironment as a Possible Underlying Mechanism of the Antitumor Effects Observed in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only